Conditions

BioMarin Pharmaceutical is making a significant move to strengthen its position in the rare disease market with the acquisition of Alesta Therapeutics. The deal will bring clinical-stage asset ALE1 into its pipeline. The transaction is valued at $275 million up front with an additional $215 million tied to development and regulatory milestones. It represents BioMarin’s…